January 06, 2026 a 07:47 am
WST: Dividend Analysis - West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc., a distinguished player in the healthcare sector, has consistently demonstrated resilience in its dividend distribution over the years. Its notable track record of 40 years of dividend history without suspensions underscores a commitment to shareholder returns. Despite a modest dividend yield, the steady growth trajectory provides a promising outlook for dividend income seekers.
📊 Overview
West Pharmaceutical Services operates in the healthcare sector, exhibiting financial stability and consistent dividend payments. Below are the key figures pertaining to its dividend profile:
| Metric | Details |
|---|---|
| Sector | Healthcare |
| Dividend yield | 0.31% |
| Current dividend per share | 0.81 USD |
| Dividend history | 40 years |
| Last cut or suspension | None |
📈 Dividend History
The company's long-standing record of dividend payments signifies reliability and stability, vital for income-focused investors. The resilience in dividend payments during economic fluctuations highlights its robust financial health.
This image represents a view of the dividend history over the recent years.
| Year | Dividend per Share (USD) |
|---|---|
| 2026 | 0.22 |
| 2025 | 0.85 |
| 2024 | 0.81 |
| 2023 | 0.77 |
| 2022 | 0.73 |
📈 Dividend Growth
Dividend growth is a crucial indicator of a company's commitment to enhancing shareholder returns. West Pharmaceutical demonstrated a moderate growth rate in its dividends over the past few years, reflecting a gradual increase in shareholder value.
| Time | Growth |
|---|---|
| 3 years | 5.20% |
| 5 years | 5.51% |
The average dividend growth is 5.51% over 5 years. This moderate yet consistent growth trend highlights steady enhancement of shareholder benefits.
This image provides visual insight into the dividend growth over recent years.
📉 Payout Ratio
The payout ratio provides insights into the sustainability of a company's dividend payments by comparing them to its earnings and free cash flow. West Pharmaceutical exhibits robust payout ratios, maintaining a balance that protects earnings while rewarding shareholders.
| Key figure | Ratio |
|---|---|
| EPS-based | 11.90% |
| Free cash flow-based | 15.36% |
The low payout ratios suggest that West Pharmaceutical sustains its dividend with a conservative approach, ensuring dividends can be upheld even during challenging periods.
📊 Cashflow & Capital Efficiency
Monitoring cash flow and capital efficiency helps determine how well a company can generate cash to meet its obligations. West Pharmaceutical presents a resilient cash flow position, providing insights into its efficient capital handling capabilities.
| Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Free Cash Flow Yield | 1.16% | 1.58% | 2.51% |
| Earnings Yield | 2.06% | 2.27% | 3.35% |
| CAPEX to Operating Cash Flow | 57.70% | 46.62% | 39.31% |
| Stock-based Compensation to Revenue | 0.65% | 0.79% | 0.82% |
| Free Cash Flow / Operating Cash Flow Ratio | 42.30% | 53.38% | 60.69% |
The solid cash flow generation and prudent capital investment strategies signify a robust capacity to fund dividends and pursue strategic growth initiatives.
📊 Balance Sheet & Leverage Analysis
An analysis of balance sheet figures and leverage ratios can help gauge a company's financial solidity and risk levels. West Pharmaceutical maintains a robust balance sheet with low leverage, signaling financial stability.
| Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt-to-Equity | 11.38% | 10.73% | 11.84% |
| Debt-to-Assets | 8.38% | 8.07% | 8.79% |
| Debt-to-Capital | 10.22% | 9.69% | 10.59% |
| Net Debt to EBITDA | -0.24 | -0.65 | -0.71 |
| Current Ratio | 0.00 | 0.00 | 0.00 |
| Quick Ratio | 2.11 | 2.24 | 2.90 |
| Financial Leverage | 1.36 | 1.33 | 1.35 |
With minimal debt levels and high liquidity ratios, West Pharmaceutical exhibits a sound financial footing to weather economic challenges and uphold shareholder interests.
📊 Fundamental Strength & Profitability
Evaluating fundamental strength and profitability metrics provides insights into the company's capacity for sustained growth and investor returns. West Pharmaceutical exhibits strong financial health with steady profitable margins.
| Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Return on Equity | 18.37% | 20.60% | 21.82% |
| Return on Assets | 13.52% | 15.50% | 16.20% |
| Margins: Net | 17.03% | 20.11% | 20.30% |
| EBIT | 20.34% | 23.95% | 23.83% |
| EBITDA | 25.71% | 28.60% | 28.01% |
| Gross | 34.65% | 38.38% | 39.47% |
| Research & Development to Revenue | 2.39% | 2.32% | 2.03% |
Strong profitability margins and returns on equity affirm West Pharmaceutical's efficient operational execution and strong financial positioning.
📈 Price Development
This image showcases the price development of West Pharmaceutical's stock in recent times.
🗣️ Dividend Scoring System
Here's an evaluation of the key dividend-related metrics through our bespoke scoring system, providing an overall picture of dividend robustness.
| Category | Score | Visual Score |
|---|---|---|
| Dividend yield | 2 | |
| Dividend Stability | 5 | |
| Dividend growth | 4 | |
| Payout ratio | 5 | |
| Financial stability | 5 | |
| Dividend continuity | 5 | |
| Cashflow Coverage | 4 | |
| Balance Sheet Quality | 5 |
Total Score: 35/40
✅ Rating
West Pharmaceutical Services, Inc. demonstrates robust financial health and steady dividend progress, making it a prudent choice for long-term dividend investors seeking moderate but reliable income growth.